Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics, Inc. director Maria Palasis reported receiving a grant of 3,997 shares of common stock on January 13, 2026. The transaction is coded as an acquisition at a price of $0 per share and is described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this award, Palasis beneficially owns 12,432 shares of Beta Bionics common stock, held in direct ownership.
Beta Bionics, Inc. director Christy Jones reported an equity award on a Form 4. On January 13, 2026, Jones acquired 3,997 shares of common stock with a transaction code "A," indicating an award rather than an open-market purchase, at a stated price of $0 per share.
The footnote explains this represents a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this grant, Jones beneficially owns 15,244 shares of Beta Bionics common stock in direct ownership.
Beta Bionics, Inc. director Adam Lezack reported an equity award of 3,997 shares of common stock. The Form 4 shows that on January 13, 2026, he acquired 3,997 shares at a price of $0 per share, reflecting a grant rather than an open-market purchase. A footnote explains that this represents a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this grant, Lezack beneficially owns 12,432 shares of Beta Bionics common stock, held directly.
Beta Bionics, Inc. director Danny L. Dearen reported an equity award of 3,997 shares of common stock. The Form 4 shows the shares were acquired on January 13, 2026 with a transaction code "A", indicating an award or grant rather than an open‑market purchase.
According to the footnote, the grant represents a restricted stock unit award issued under the company’s 2025 Equity Incentive Plan at a stated price of $0 per share, which is typical for RSU grants. After this transaction, Dearen beneficially owns 15,244 shares of Beta Bionics common stock, held directly.
Beta Bionics, Inc. filed a current report to disclose that it has issued a press release with preliminary, unaudited fourth quarter 2025 topline financial results and key operating metrics. The company furnished this information under its results of operations and financial condition disclosure and attached the press release as Exhibit 99.1. The report clarifies that these materials are being furnished rather than filed, which affects how they are treated under securities law.
Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a planned sale of company stock. On January 6, 2026, he sold 2,200 shares of common stock at a weighted average price of $30.1005 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, he beneficially owned 80,752 shares of Beta Bionics common stock directly. The filing notes that individual sale prices ranged between $30.00 and $30.13, and detailed breakdowns are available to regulators, the company, or its security holders on request.
Beta Bionics (BBNX) insider activity: A director reported open-market sales of common stock on 10/31/2025 made under a Rule 10b5-1 plan adopted on July 31, 2025. The filings show two transactions: 1,368 shares sold at a weighted average price of $26.8474 (with individual sale prices ranging from $26.27 to $27.24), and 38 shares sold at $27.70.
Following these sales, the reporting person beneficially owned 9,841 shares, held directly. The form notes that full breakdowns of the number of shares sold at each separate price within the weighted-average transaction are available upon request.
Beta Bionics (BBNX) director reported open-market sales on 10/31/2025 under a Rule 10b5-1 plan adopted July 31, 2025. Two transactions were disclosed: 1,287 shares at a weighted average price of $26.8588 (range $26.27–$27.22) and 119 shares at a weighted average price of $27.4502 (range $27.32–$27.57).
Following these trades, the reporting person directly beneficially owns 9,841 shares. The filing notes full trade breakdowns by price increment are available upon request.
Beta Bionics (BBNX) reported Q3 results showing rapid top-line growth as it scales commercialization of the iLet Bionic Pancreas. Net sales were $27.3 million for the quarter, up from $16.7 million a year ago, driven by both device and recurring single‑use products across durable medical equipment and pharmacy channels. Gross profit reached $15.1 million, reflecting higher volumes.
Operating expenses rose with commercialization: research and development $8.2 million, sales and marketing $16.0 million, and general and administrative $7.9 million. The company posted a net loss of $14.2 million in Q3 and $59.7 million for the nine months. Loss per share was $0.33 on 43.6 million weighted‑average shares.
Liquidity strengthened post‑IPO. As of September 30, 2025, cash and cash equivalents were $38.5 million, short‑term investments $190.2 million, and long‑term investments $45.3 million. Total assets were $330.0 million and stockholders’ equity was $294.8 million. In January 2025, the company completed an IPO with approximately $190.4 million in net proceeds and a $15.6 million concurrent private placement; preferred stock and certain warrants converted to common. Shares outstanding were 44,024,631 as of October 24, 2025.
Beta Bionics, Inc. reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The release is included as Exhibit 99.1.
The information under Item 2.02 is furnished and is not deemed “filed” under the Exchange Act or incorporated by reference unless expressly stated otherwise.